Reference health
Vaccination for SARS-CoV-2 in Patients With Psoriatic Arthritis: Can Therapy Affect the Immunological Response?
1 of 40 checkable references need attention · checked 2026-07-23
At the dated check, the references listed below either did not resolve in Crossref or DataCite, or carried a retraction notice. Each one is shown with the registry record that put it there.
1 without a DOI — not checked. A reference deposited without a DOI is never matched by title or guessed at; it stays outside the checked set, and this line discloses that.
References needing attention
does not resolve to a known work10.1002/art.42030.
The 39 checked references that resolve
resolves10.1007/s12016-017-8630-7
Clinical Features of Psoriatic Arthritis: a Comprehensive Review of Unmet Clinical Needs
resolves10.1136/rmdopen-2017-000588
Real-world burden of comorbidities in US patients with psoriatic arthritis
resolves10.1136/annrheumdis-2020-217871
Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry
resolves10.1136/annrheumdis-2020-218946
Prevalence and clinical outcomes of COVID-19 in patients with autoimmune diseases: a systematic review and meta-analysis
resolves10.1002/art.41301
American College of Rheumatology Guidance for the Management of Rheumatic Disease in Adult Patients During the COVID‐19 Pandemic: Version 1
resolves10.1136/annrheumdis-2020-217877
EULAR provisional recommendations for the management of rheumatic and musculoskeletal diseases in the context of SARS-CoV-2
resolves10.1136/annrheumdis-2021-220461
SARS-CoV-2 vaccination responses in untreated, conventionally treated and anticytokine-treated patients with immune-mediated inflammatory diseases
resolves10.1136/annrheumdis-2021-220289
Antibody response to a single dose of SARS-CoV-2 mRNA vaccine in patients with rheumatic and musculoskeletal diseases
resolves10.1136/annrheumdis-2021-220272
Immunogenicity and safety of anti-SARS-CoV-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort
resolves10.1136/annrheumdis-2021-220597
Methotrexate hampers immunogenicity to BNT162b2 mRNA COVID-19 vaccine in immune-mediated inflammatory disease
resolves10.1016/S2665-9913(21)00333-7
Humoral and cellular immunogenicity to a second dose of COVID-19 vaccine BNT162b2 in people receiving methotrexate or targeted immunosuppression: a longitudinal cohort study
resolves10.1136/annrheumdis-2018-213222
Impact of temporary methotrexate discontinuation for 2 weeks on immunogenicity of seasonal influenza vaccination in patients with rheumatoid arthritis: a randomised clinical trial
resolves10.1016/j.autrev.2021.102927
Response to SARS-CoV-2 vaccination in immune mediated inflammatory diseases: Systematic review and meta-analysis
resolves10.1136/annrheumdis-2015-207507
Disease activity in psoriatic arthritis (PsA): defining remission and treatment success using the DAPSA score
resolves10.1002/art.41437
American College of Rheumatology Guidance for the Management of Rheumatic Disease in Adult Patients During the COVID‐19 Pandemic: Version 2
resolves10.1016/j.jaad.2020.12.058
National Psoriasis Foundation COVID-19 Task Force guidance for management of psoriatic disease during the pandemic: Version 2—Advances in psoriatic disease management, COVID-19 vaccines, and COVID-19 treatments
resolves10.1111/bjd.20479
Antibody responses to single‐dose SARS‐CoV‐2 vaccination in patients receiving immunomodulators for immune‐mediated inflammatory disease
resolves10.7326/M21-1757
Effect of Immunosuppression on the Immunogenicity of mRNA Vaccines to SARS-CoV-2
resolves10.1016/j.jaad.2021.10.034
Incidence and severity of COVID-19 in patients with autoimmune blistering skin diseases: A nationwide study
resolves10.1016/j.jaad.2020.12.043
Characteristics and outcomes of COVID-19 in patients with autoimmune bullous diseases: A retrospective cohort study
resolves10.3389/fimmu.2021.740249
ImmunosuppressiveTherapies Differently Modulate Humoral- and T-Cell-Specific Responses to COVID-19 mRNA Vaccine in Rheumatoid Arthritis Patients
resolves10.3390/vaccines8040728
The Risk of COVID-19 Pandemic in Patients with Moderate to Severe Plaque Psoriasis Receiving Systemic Treatments
resolves10.1080/14712598.2021.1853698
Characteristic of chronic plaque psoriasis patients treated with biologics in Italy during the COVID-19 Pandemic: Risk analysis from the PSO-BIO-COVID observational study
resolves10.1016/j.jaci.2020.10.032
Incidence rates of hospitalization and death from COVID-19 in patients with psoriasis receiving biological treatment: A Northern Italy experience
resolves10.1016/j.jbspin.2020.105095
COVID-19 in French patients with chronic inflammatory rheumatic diseases: Clinical features, risk factors and treatment adherence
resolves10.1007/s00296-020-04676-4
Coronavirus disease 2019 (COVID-19) in autoimmune and inflammatory conditions: clinical characteristics of poor outcomes
resolves10.1136/annrheumdis-2020-218054
Clinical course, severity and mortality in a cohort of patients with COVID-19 with rheumatic diseases
resolves10.1016/j.jaci.2020.10.007
Factors associated with adverse COVID-19 outcomes in patients with psoriasis—insights from a global registry–based study
resolves10.1371/journal.pone.0233147
Prevalence, Severity and Mortality associated with COPD and Smoking in patients with COVID-19: A Rapid Systematic Review and Meta-Analysis
resolves10.1371/journal.pmed.1003374
Rapid Epidemiological Analysis of Comorbidities and Treatments as risk factors for COVID-19 in Scotland (REACT-SCOT): A population-based case-control study
resolves10.1016/j.ijid.2020.07.029
Comorbidities and the risk of severe or fatal outcomes associated with coronavirus disease 2019: A systematic review and meta-analysis
resolves10.1038/s41467-020-19741-6
Male sex identified by global COVID-19 meta-analysis as a risk factor for death and ITU admission
resolves10.1136/annrheumdis-2021-221244
Impact of disease-modifying antirheumatic drugs on vaccine immunogenicity in patients with inflammatory rheumatic and musculoskeletal diseases
The 1 reference without a DOI — listed, not checked
no DOI — not checkedA review for physician assistants and nurse practitioners on the considerations for diagnosing and treating psoriatic arthritis
What this badge says. CiteStamped means the CHECKABLE references of this
work were clean at the dated check: each resolved to a known work in a public registry, and none
carried a retraction notice at that time. It says nothing about the quality, findings,
or importance of the work itself, and nothing about references deposited without a DOI.
checked 2026-07-23 — re-checked daily as this page is visited; titles and statuses come from Crossref and DataCite and are not part of the signed record
Embed this badge
Both snippets point at the live badge image and link back to this page. The badge re-renders from the daily check, so an embed never goes stale by more than a day of visits.
<a href="https://citestamp.com/citestamped/10.3389/fmed.2022.811829"><img src="https://citestamp.com/citestamped/10.3389/fmed.2022.811829/badge.svg" alt="CiteStamped reference-health badge" width="460" height="64"></a>
[](https://citestamp.com/citestamped/10.3389/fmed.2022.811829)